



**Australian Government**

---

**Department of Health and Ageing**

**SCHEDULE OF PHARMACEUTICAL BENEFITS  
FOR DENTAL PRACTITIONERS**

This Schedule is also available on the internet at  
[www.pbs.gov.au](http://www.pbs.gov.au)

**SUMMARY OF CHANGES**

**EFFECTIVE 1 July 2011**

© Commonwealth of Australia 2011

ISSN 1037-3667

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at <http://www.ag.gov.au/cca>

This Schedule provides information on the arrangements for the prescribing and supply of pharmaceutical benefits. These arrangements operate under the *National Health Act 1953*. However, at the time of printing, the relevant legislation giving authority for the changes included in this issue of the Schedule may still be subject to the usual Parliamentary scrutiny. This book is not a legal document, and, in cases of discrepancy, the legislation will be the source document for payment for the supply of pharmaceutical benefits. The legislation is available from the Federal Register of Legislative Instruments website at <http://www.frli.gov.au>.

The information is not intended to give or replace any legal, medical, dental or optometrical advice. This document is not a legal document and does not constitute legal advice. Neither the information nor this document can be relied upon without first seeking and obtaining independent legal, medical, dental or optometrical advice beforehand. To the extent permitted by law, the Commonwealth of Australia will not be held responsible, nor accept any liability (whether arising out of negligence or otherwise), for any injury, damages, costs, expenses and losses suffered or incurred by a person where such a person has relied on this document or used the information in it as legal, medical, dental or optometrical advice.

## PHARMACEUTICAL BENEFITS

These changes to the Schedule of Pharmaceutical Benefits of Dental Practitioners are effective from 1 July 2011. The Schedule is updated on the first day of each month and is available on the Internet at [www.pbs.gov.au](http://www.pbs.gov.au).

### SUMMARY OF CHANGES

#### Additions

##### Additions – Brands

- 5083M *Vycin IV, WQ* – **Vancomycin**, Powder for injection 1 g (as hydrochloride) (1,000,000 i.u. vancomycin activity)  
 3323X *Vycin IV, WQ* – **Vancomycin**, Powder for injection 500 mg (as hydrochloride) (500,000 i.u. vancomycin activity)

#### Deletions

##### Deletions – Items

- 5023J **Hydromorphone Hydrochloride**, Tablet 4 mg (modified release) (*Jurnista*)  
 3357Q **Hydromorphone Hydrochloride**, Tablet 8 mg (modified release) (*Jurnista*)  
 3358R **Hydromorphone Hydrochloride**, Tablet 16 mg (modified release) (*Jurnista*)  
 3367F **Hydromorphone Hydrochloride**, Tablet 32 mg (modified release) (*Jurnista*)  
 3368G **Hydromorphone Hydrochloride**, Tablet 64 mg (modified release) (*Jurnista*)  
 5129Y **Hydromorphone Hydrochloride**, Injection 2 mg in 1 mL (*Dilaudid*)  
 5130B **Hydromorphone Hydrochloride**, Injection 10 mg in 1 mL (*Dilaudid-HP*)  
 5131C **Hydromorphone Hydrochloride**, Injection 50 mg in 5 mL (*Dilaudid-HP*)  
 5159M **Metronidazole**, Tablet 400 mg (*Metrogyl 400*)  
 5162Q **Morphine Sulfate**, Tablet 5 mg (controlled release) (*MS Contin*)  
 5164T **Morphine Sulfate**, Tablet 10 mg (controlled release) (*Momex SR 10, MS Contin*)  
 5161P **Morphine Sulfate**, Tablet 15 mg (controlled release) (*MS Contin*)  
 5165W **Morphine Sulfate**, Tablet 30 mg (controlled release) (*Momex SR 30, MS Contin*)  
 5166X **Morphine Sulfate**, Tablet 60 mg (controlled release) (*Momex SR 60, MS Contin*)  
 5167Y **Morphine Sulfate**, Tablet 100 mg (controlled release) (*Momex SR 100, MS Contin*)  
 5246D **Morphine Sulfate**, Capsule 10 mg (containing sustained release pellets) (*Kapanol*)  
 5240T **Morphine Sulfate**, Capsule 20 mg (containing sustained release pellets) (*Kapanol*)  
 5064M **Morphine Sulfate**, Capsule 30 mg (controlled release) (*MS Mono*)  
 5241W **Morphine Sulfate**, Capsule 50 mg (containing sustained release pellets) (*Kapanol*)  
 5065N **Morphine Sulfate**, Capsule 60 mg (controlled release) (*MS Mono*)  
 5066P **Morphine Sulfate**, Capsule 90 mg (controlled release) (*MS Mono*)  
 5242X **Morphine Sulfate**, Capsule 100 mg (containing sustained release pellets) (*Kapanol*)  
 5067Q **Morphine Sulfate**, Capsule 120 mg (controlled release) (*MS Mono*)  
 5171E **Morphine Sulfate**, Sachet containing controlled release granules for oral suspension, 20 mg per sachet (*MS Contin Suspension 20 mg*)  
 5243Y **Morphine Sulfate**, Sachet containing controlled release granules for oral suspension, 30 mg per sachet (*MS Contin Suspension 30 mg*)  
 5244B **Morphine Sulfate**, Sachet containing controlled release granules for oral suspension, 60 mg per sachet (*MS Contin Suspension 60 mg*)  
 5245C **Morphine Sulfate**, Sachet containing controlled release granules for oral suspension, 100 mg per sachet (*MS Contin*)

*Suspension 100 mg)*

- 5227D **Oxycodone Hydrochloride**, Tablet 5 mg (controlled release) (*OxyContin*)
- 5247E **Oxycodone Hydrochloride**, Tablet 10 mg (controlled release) (*OxyContin*)
- 5015Y **Oxycodone Hydrochloride**, Tablet 15 mg (controlled release) (*OxyContin*)
- 5248F **Oxycodone Hydrochloride**, Tablet 20 mg (controlled release) (*OxyContin*)
- 5016B **Oxycodone Hydrochloride**, Tablet 30 mg (controlled release) (*OxyContin*)
- 5249G **Oxycodone Hydrochloride**, Tablet 40 mg (controlled release) (*OxyContin*)
- 5250H **Oxycodone Hydrochloride**, Tablet 80 mg (controlled release) (*OxyContin*)
- 5198N **Oxycodone Hydrochloride**, Capsule 20 mg (*OxyNorm*)
- 3338Q **Tramadol Hydrochloride**, Tablet 50 mg (twice daily sustained release) (*Tramal SR 50*)
- 5001F **Tramadol Hydrochloride**, Tablet 100 mg (once a day extended release) (*Durotram XR*)
- 5234L **Tramadol Hydrochloride**, Tablet 100 mg (twice daily sustained release) (*Tramal SR 100, Zydol SR 100, Tramedo SR 100, APO-Tramadol SR, Chem mart Tramadol SR, Terry White Chemists Tramadol SR, Lodam SR 100, GA Tramadol SR 100mg, Tramadol Sandoz SR*)
- 5235M **Tramadol Hydrochloride**, Tablet 150 mg (twice daily sustained release) (*Tramal SR 150, Zydol SR 150, Tramedo SR 150, APO-Tramadol SR, Chem mart Tramadol SR, Terry White Chemists Tramadol SR, Lodam SR 150, GA Tramadol SR 150mg, Tramadol Sandoz SR*)
- 5002G **Tramadol Hydrochloride**, Tablet 200 mg (once a day extended release) (*Durotram XR*)
- 5236N **Tramadol Hydrochloride**, Tablet 200 mg (twice daily sustained release) (*Tramal SR 200, Zydol SR 200, Tramedo SR 200, APO-Tramadol SR, Chem mart Tramadol SR, Terry White Chemists Tramadol SR, Lodam SR 200, GA Tramadol SR 200mg, Tramadol Sandoz SR*)
- 5003H **Tramadol Hydrochloride**, Tablet 300 mg (once a day extended release) (*Durotram XR*)

## Alterations

### Alterations – Brand Name

*From:*

5257Q *Aspen Pharmacare Australia Pty Limited, LN – Flucloxacillin*, Powder for oral liquid 125 mg (as sodium) per 5 mL, 100 mL

*To:*

5257Q *Flucil, LN – Flucloxacillin*, Powder for oral liquid 125 mg (as sodium) per 5 mL, 100 mL

*From:*

5258R *Aspen Pharmacare Australia Pty Limited, LN – Flucloxacillin*, Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL

*To:*

5258R *Flucil, LN – Flucloxacillin*, Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL

### Alterations – Manufacturer's Code

All items with the manufacturer code SH have changed to the code MK.

		<i>From:</i>	<i>To:</i>
3363B	<i>LPV, VT – Phenoxymethylpenicillin</i> , Capsule 250 mg	AS	VT
3364C	<i>LPV, VT – Phenoxymethylpenicillin</i> , Capsule 500 mg	AS	VT

**PREPARATIONS WHICH MAY BE PRESCRIBED BY PARTICIPATING  
DENTAL PRACTITIONERS FOR DENTAL TREATMENT ONLY**

Code	Name, Restriction, Manner of Administration and Form	Max. Qty	No. of Rpts	Premium	Dispensed Price	Maximum	Brand Name and Manufacturer
					for Max. Qty \$	Recordable Value for Safety Net \$	
<b>FLUCLOXACILLIN</b>							
<b>Caution</b>							
Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days.							
<b>Restricted benefit</b>							
Serious staphylococcal infections.							
5258R	Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL <b>(Dental)</b>	‡1	..	..	#19.53	20.94	Flucil LN
5257Q	Powder for oral liquid 125 mg (as sodium) per 5 mL, 100 mL <b>(Dental)</b>	‡1	..	..	#16.00	17.41	Flucil LN
<b>PHENOXYMETHYLPENICILLIN</b>							
3363B	Capsule 250 mg <b>(Dental)</b>	50	..	..	11.16	12.23	<sup>a</sup> Cilicaine VK FM <sup>a</sup> Cilopen VK GM LPV VT
3364C	Capsule 500 mg <b>(Dental)</b>	50	..	..	13.47	14.54	<sup>a</sup> Cilicaine VK FM <sup>a</sup> Cilopen VK GM LPV VT
<b>VANCOMYCIN</b>							
<b>Restricted benefit</b>							
Prophylaxis of endocarditis in patients hypersensitive to penicillin.							
5083M	Powder for injection 1 g (as hydrochloride) (1,000,000 i.u. vancomycin activity) <b>(Dental)</b>	1	..	..	16.52	17.59	<sup>a</sup> Hospira Pty Limited HH <sup>a</sup> Vancomycin Alphapharm AF <sup>a</sup> Vancomycin Sandoz SZ <sup>a</sup> Vycin IV WQ
3323X	Powder for injection 500 mg (as hydrochloride) (500,000 i.u. vancomycin activity) <b>(Dental)</b>	2	..	..	*16.52	17.59	<sup>a</sup> Hospira Pty Limited HH <sup>a</sup> Vancocin CP AS <sup>a</sup> Vancomycin Alphapharm AF <sup>a</sup> Vancomycin Sandoz SZ <sup>a</sup> Vycin IV WQ